Skip to content

Cognitive Decline in Fatty Liver patients

Incidence of Neurocognitive Decline Across Treatment Modalities in MASLD: A 1-Year Prospective Pilot Study - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2025/09/094002
Enrollment
100
Registered
2025-09-01
Start date
Unknown
Completion date
Unknown
Last updated
2025-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K760- Fatty (change of) liver, not elsewhere classified

Interventions

Intervention1: Nil: Nil

Sponsors

Dr Yashashri Shetty
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Any patients with normal range liver function tests and fibroscan showing spleen stiffness measurement less than forty five

Exclusion criteria

Exclusion criteria: Patients with alcoholic liver disease uncontrolled diabetes kidney failure and hypertension vascular diseases mental and behavioral disorders decompensated liver cirrhosis and hepatobiliary disorders pregnant and lactating women patients with malignancies history of serious drug allergies

Design outcomes

Primary

MeasureTime frame
Incidence of neurocognitive decline measured using the montreal cognitive assessment scaleTimepoint: at baseline then six months and one year treatment period

Secondary

MeasureTime frame
change in quality of life scores serum biomarker levels liver function tests lipid profiles and fibroscan and incidence of any adverse eventsTimepoint: at baseline six months and one year treatment period

Countries

India

Contacts

Public ContactDr Jannvi Sharma

Seth GS Medical College and KEM Hospital

jaanvisharma0512@gmail.com9987774393

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026